Ipamorelin

Everyone heard "peptides are coming back." Almost nobody heard that the FDA already sat down with some of the most-stacked ones and voted no. Here's which, when, and what a July 2026 yes would actually buy you.

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

CJC-1295, ipamorelin, sermorelin, and tesamorelin share one job — getting your own pituitary to release more growth hormone, the repair-and-recovery signal that fades after your twenties. Here is the appeal, the two peptide families inside the class, and how far the human proof actually goes.

CJC-1295 and ipamorelin are the internet's favourite growth-hormone pairing — but they do two different jobs. One raises your GH baseline for days from a single shot; the other fires a clean nightly pulse. Here's what each could do for you, which fits which goal, and why so many people run both.

Ipamorelin asks your own body to release a clean pulse of growth hormone — the recovery, sleep and body-composition signal — without the stress-hormone mess older compounds caused. Here's what that could mean for you, and how far the human proof actually goes.

You've probably met ipamorelin as the second half of CJC-1295 and ipamorelin. On its own it's the quieter half — a small peptide built to ask your own body for a clean pulse of growth hormone. Here's what it could mean for you, why it earned the clean name, and how far the human proof goes.

CJC-1295 reliably raises GH and IGF-1 in humans, confirmed by a single 2006 pharmacokinetic study. Whether that translates into any functional benefit has never been tested.